
3M Young Scientist Challenge Announces 2025 National Finalists
ST. PAUL, Minn. and CHARLOTTE, N.C., June 25, 2025 /3BL/ - 3M (@3M) and Discovery Education (@DiscoveryEd) today announced the 2025 3M Young Scientist Challenge ( #YoungScientist ) top 10 finalists. As the nation's premier middle school science competition, the annual 3M Young Scientist Challenge invites students in grades 5-8 to compete for an exclusive mentorship with a 3M scientist, a $25,000 grand prize, and the chance to earn the title of 'America's Top Young Scientist.'
The top 10 2025 3M Young Scientist Challenge finalists are as follows (in alphabetical order by last name):
'For 18 years, the 3M Young Scientist Challenge has empowered middle school students to bring science to life,' said Torie Clarke, 3M's executive vice president and chief public affairs officer. 'This year, the nation's brightest young minds have once again reimagined what's possible. Congratulations to each of the top 10 finalists! I can't wait to see how you make the world a better place.'
To learn more about the 3M Young Scientist Challenge and meet the 2025 finalists, visit YoungScientistLab.com.
Challenge detailsThis year's finalists – 10 students ranging in age from 11-14 – identified an everyday problem and submitted a one- to two-minute video on their proposed scientific solution. Their proposals fall under an expanded set of entry categories, including robotics, home improvement, automotive, safety, AR/VR, and climate technology.
An esteemed group of judges, including 3M scientists and leaders in education from across the country, evaluated entries based on creativity, scientific knowledge, and communication effectiveness.
Next stepsEach of the 10 finalists will participate in an exclusive summer mentorship program with a 3M scientist. These mentors will provide guidance and advice to help advance their finalist's solution. Then, from Oct. 13-14, each finalist will travel to the 3M Innovation Center in St. Paul, Minn., for the final interactive competition.
At 3M, each finalist will participate in a series of challenges, including a presentation of their completed innovation, and be scored independently by a panel of judges. The grand prize winner will be announced, and they will receive $25,000, a unique destination trip, and the title of America's Top Young Scientist.
Previous winnersPrevious challenge finalists and 3M scientists have collaborated to create solutions for a wide variety of real-world problems, including cybersecurity, coral reef health, water conservation, food waste, alternative energy sources, energy consumption, air pollution, and transportation efficiency.
The 2024 winner – 14-year-old Sirish Subash from Snellville, Georgia. – created PestiSCAND, a handheld device designed to detect pesticide residues on produce using a non-destructive method. The innovation employs spectrophotometry, which involves measuring how light of various wavelengths is reflected off the surface of fruits and vegetables. A machine-learning model then analyzes this data to determine the presence of pesticides.
Now in its eighteenth year, the 3M Young Scientist Challenge continues to inspire and challenge middle school students to think creatively and apply the power of STEM to discover real-world solutions. Former America's Top Young Scientists have given TED Talks, filed patents, founded nonprofits, made the Forbes 30 Under 30 list, and exhibited at the White House Science Fair. These young innovators have also been named TIME Magazine's Kid of the Year; featured in The New York Times Magazine, Forbes, and Business Insider; and appeared on national television programs such as Good Morning America, The Kelly Clarkson Show, and more. In addition, a 3M Young Scientist Challenge Alumni Network was formed in fall 2022 and includes more than 100 former challenge winners, finalists, and mentors, who take part in networking opportunities and more.
'The 3M Young Scientist Challenge exemplifies the power of nurturing student curiosity by preparing students for the future, today. We are delighted to celebrate these young scientists for their commitment to solving real-world problems with innovation, creativity, and ingenuity,' said Amy Nakamoto, Executive Vice President of Marketing and Corporate Partnerships at Discovery Education.
The award-winning competition supplements the 3M and Discovery Education program Young Scientist Lab, which provides no-cost dynamic digital resources for students, teachers, and families to explore, transform, and innovate the world around them. All the resources are also available on Discovery Education Experience, the essential companion for engaged PreK-12 classrooms.
###
About 3M3M (NYSE: MMM) believes science helps create a brighter world for everyone. By unlocking the power of people, ideas and science to reimagine what's possible, our global team uniquely addresses the opportunities and challenges of our customers, communities, and planet. Learn how we're working to improve lives and make what's next at 3M.com/news-center.
About Discovery EducationDiscovery Education is the worldwide edtech leader whose state-of-the-art, Pre-K-12, digital solutions support learning wherever it takes place. Through award-winning multimedia content, instructional supports, innovative classroom tools, and strategic alliances, Discovery Education helps educators deliver powerful learning experiences that engage all students and support higher academic achievement on a global scale. Discovery Education serves approximately 4.5 million educators and 45 million students worldwide, and its resources are accessed in over 100 countries and territories. Through partnerships with districts, states, and trusted organizations, Discovery Education empowers teachers with essential edtech solutions that inspire curiosity, build confidence, and accelerate learning. Explore the future of education at www.discoveryeducation.com.
ContactsTim Post 3MEmail: [email protected]
Grace MaliskaDiscovery EducationEmail: [email protected]
Visit 3BL Media to see more multimedia and stories from Discovery Education
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
36 minutes ago
- Yahoo
Gilead, Kymera Partner in $750M Deal to Develop Novel Molecular Glue Degraders for Cancer
Gilead Sciences Inc. (NASDAQ:GILD) is one of the undervalued S&P 500 stocks to buy according to hedge funds. On June 25, Gilead Sciences expanded its oncology pipeline through an exclusive agreement with Kymera Therapeutics Inc. (NASDAQ:KYMR). This deal is potentially valued at up to $750 million and focuses on advancing Kymera's innovative molecular glue degrader/MGD program targeting cyclin-dependent kinase 2/CDK2. Gilead will make an upfront payment of up to $85 million, with additional payments contingent on future development milestones and product sales, plus tiered royalties on net product sales. Kymera's MGDs are designed to selectively eliminate CDK2, which is a protein crucial for cell division that often drives uncontrolled growth in various cancers, such as breast cancer and other solid tumors. A physician and a patient having a discussion in a hospital about biopharmaceutical medicines. Unlike traditional CDK2 inhibitors that merely block protein activity, MGDs aim to remove the protein entirely. Kymera will lead all research activities for the CDK2 program. If Gilead exercises its option, it will gain worldwide rights to develop, manufacture, and commercialize all resulting products. This move for Gilead follows closely on the heels of the US FDA approval of Yeztugo (lenacapavir) for HIV prevention. Gilead Sciences Inc. (NASDAQ:GILD) is a biopharmaceutical company that discovers, develops, and commercializes medicines in the areas of unmet medical needs. Kymera Therapeutics Inc. (NASDAQ:KYMR) is a clinical-stage biopharmaceutical company that discovers and develops small-molecule therapeutics. While we acknowledge the potential of GILD as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the . READ NEXT: and . Disclosure: None. This article is originally published at Insider Monkey. Sign in to access your portfolio
Yahoo
an hour ago
- Yahoo
BioMarin's ROCTAVIAN Shows Sustained Efficacy, Safety Over 5 Years for Severe Hemophilia A
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) is one of the most undervalued US stocks according to analysts. On June 24, BioMarin Pharmaceutical Inc. presented new 5-year data from its Phase 3 GENEr8-1 trial at the 33rd Congress of the International Society on Thrombosis and Haemostasis/ISTH in Washington, D.C., which took place from June 21 to 25. The data reinforced the long-term efficacy and safety of ROCTAVIAN (valoctocogene roxaparvovec-rvox) as a gene therapy for severe hemophilia A. The GENEr8-1 trial is the longest and largest hemophilia gene therapy study to date, and demonstrated sustained Factor VIII (FVIII) expression and durable bleed control 5 years after a single treatment with ROCTAVIAN. A pharmaceutical plant manufacturing a proprietary synthetic oral form of a C-type natriuretic peptide. FVIII activity remained consistent with previously reported results. Importantly, no new safety signals were observed over the 5-year study period. Across all 134 participants who received ROCTAVIAN in the study, there were no cases of FVIII inhibitors or thromboembolic events, and no treatment-related malignancies were observed. BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) is a biotechnology company that develops and commercializes therapies for life-threatening rare diseases and medical conditions internationally. While we acknowledge the potential of BMRN as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the . READ NEXT: and . Disclosure: None. This article is originally published at Insider Monkey. Sign in to access your portfolio
Yahoo
an hour ago
- Yahoo
United Therapeutics Announces World's First Bioengineered External Liver Treatment in Clinical Study
United Therapeutics Corporation (NASDAQ:UTHR) is one of the most undervalued US stocks according to analysts. On June 24, United Therapeutics Corporation and Intermountain Health announced a medical breakthrough: the world's first patient treated in a clinical study with a bioengineered external liver assist product called miroliverELAP. This historic procedure marked the first human clinical trial of a manufactured organ alternative and was performed at Intermountain Medical Center in Murray, Utah, by a team led by Christopher J. Danford, MD, who is a transplant hepatologist at Intermountain Health. The patient treated was experiencing liver failure and was not eligible for a liver transplant. A team of scientists in a laboratory, running tests on a biotechnology product. MiroliverELAP was developed by Miromatrix Medical Inc., which is a subsidiary of United Therapeutics and is an external liver assist combination product. It comprises a single-use MIRO-001 bioengineered liver and an extracorporeal blood circuit, designed to provide temporary liver support for patients with acute liver failure/ALF. ALF is a severe condition characterized by a rapid loss of liver function, often in individuals with no prior history of liver disease. United Therapeutics Corporation (NASDAQ:UTHR) is a biotechnology company that develops and commercializes products to address the unmet medical needs of patients with chronic and life-threatening diseases internationally. While we acknowledge the potential of UTHR as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the . READ NEXT: and . Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data